Par Sues FDA To Get "Tailored" Rules On Off-Label Promotion
This article was originally published in The Pink Sheet Daily
Executive Summary
Par claims it is being blocked from informing physicians about the approved use of Megace ES; the case could be derailed by a DoJ complaint against Par, as was Allergan's suit against FDA.
You may also be interested in...
When Is On-Label Speech Off-Label Promotion? Par Links The Two In Suit Against FDA
Par Pharmaceutical Inc.’s First Amendment suit against FDA offers a new approach to battling government allegations of off-label marketing.
When Is On-Label Speech Off-Label Promotion? Par Links The Two In Suit Against FDA
Par Pharmaceutical Inc.’s First Amendment suit against FDA offers a new approach to battling government allegations of off-label marketing.
Sales Rep's Free Speech Challenge Of Off-Label Regs Boosted By Sorrell Ruling
The Supreme Court's ruling that Vermont's prescriber data mining law violates the First Amendment could help a pharma sales representative to overturn his conviction for promoting a drug for off-label uses.